We are glad to announce the following distinguished researchers as keynote speakers for the GlycoBioTec2023:
Peter H. Seeberger studied chemistry in Erlangen (Germany) and completed a PhD in biochemistry in Boulder (USA). After a postdoctoral fellowship at the Sloan-Kettering Cancer Center Research in New York he advanced to tenured Firmenich Associate Professor of Chemistry at MIT. After six years as Professor at the Swiss Federal Institute of Technology (ETH) Zurich he assumed positions as Director at the Max-Planck Institute for Colloids and Interfaces in Potsdam and Professor at the Free University of Berlin in 2009. Since 2021, he is a Vice President of the German Research Foundation (DFG) the main funding body in Germany. He is a member of the governing body of the Max-Planck Society (“Senate”) and the Veterinary University (TiHo) Hannover (“Stiftungsrat”). Professor Seeberger’s research has been documented in over 630 peer-reviewed journal articles, five books, more than 50 patents, and more than 900 invited lectures. This work was recognized with more than 35 international awards. Seeberger has been the Editor-in-Chief of the platinum open access Beilstein Journal of Organic Chemistry and serves on the editorial advisory boards of many other journals. He is a co-founder of the Tesfa-Ilg “Hope for Africa” Foundation. The research in the Seeberger laboratory has given rise to several successful companies in the USA, Switzerland, Denmark and Germany.
Rita Gerardy-Schahn is professor for Molecular Biology and Biochemistry at the Hannover Medical School. Her responsibilities are research and education. Her research focus is the molecular characterization of enzymes along the (poly)sialylation pathways of mammalian and bacterial cells. Her team identified central factors along these pathways and invested in the establishment of tools, with which (poly)sialoglycans can be specifically recognized and degraded. Her team has established constitutive as well as conditional animal models to analyze the functions of enzymes of interest under complex physiological conditions. Over the past seven years, she refocused her studies at applied sciences aspects involving the exploitation of characterized enzymes for the production of vaccines.
Horst Bierau is a Senior Scientific Advisor and heads the CMC Science & Intelligence group in the Healthcare division of Merck. He has 20 years of experience in biopharmaceutical product development for a variety of disease indications and his research interests focus on CMC development.
Kaspar Locher studied Chemistry/Biochemistry at the Swiss Federal Institute of Technology (ETH) Zurich. He obtained a PhD in Biochemistry from the University of Basel in 1998, where he pursued studies with Prof. J. Rosenbusch at the Biozentrum. From 1999-2003, he was a post-doctoral researcher with Prof. Douglas Rees at the California Institute of Technology. In 2003, he joined ETH Zurich as an Assistant Professor and was promoted to Full Professor of Molecular Membrane Biology in 2013. Locher is interested in the structural and mechanistic studies of membrane proteins. His research focus includes the investigation of glycosyltransferases that are part of the protein N-glycosylation machinery. His goal is to assemble molecular "movies" of these essential biochemical reactions by combining high resolution protein structures with biochemical and biophysical studies. In addition to generating insight into the mechanism of physiologically important reactions, his studies provide opportunities for future drug discovery.
Lai-Xi Wang is Professor of Chemistry and Biochemistry at the University of Maryland, College Park. He received his PhD from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. After postdoctoral studies in glycobiology and molecular biology at Johns Hopkins University and MIT, respectively, he joined the faculty of University of Maryland as an assistant professor in 2000 and was promoted to full professor in 2009. His research focuses on development of new chemoenzymatic methods for glycoprotein synthesis and antibody glycoengineering and on their applications for functional studies and drug discovery. The site-specific Fc glycan remodeling method developed by his team enables a quick access to various homogeneous antibody glycoforms for immunological studies. More recently, his team has developed a general and efficient chemoenzymatic approach for site-specific antibody labeling and bioconjugation. It provides a platform technology for producing homogeneous antibody-drug conjugates and antibody-ligand conjugates for therapeutic development.
Pauline M. Rudd (PMR) BSc, LRIC, MA (Oxon), FISSR, PhD is an Emeritus Fellow of the Conway Institute University College Dublin and Visiting Investigator at the Bioprocessing Technology Institute, AStar, Singapore. From 2006-2018 she was NIBRT Professor of Glycoproteomics and Glycobiology at University College, Dublin heading the NIBRT GlycoScience Group. PMR obtained a BSc in Chemistry at the University of London and a PhD in Glycobiology at the Open University, UK. She was a Founding Scientist of Wessex Biochemicals (later Sigma London) and after a long career break to raise 4 children, a member of the Oxford Glycobiology Institute for 25 years and a University Reader. She was a visiting scientist at The Scripps Research Institute, CA, Shanghai Medical University PRC, Ben Gurion University of the Negev, Israel and an Erskine Visiting Fellow, Canterbury University, Christchurch, New Zealand. She is a Fellow of the Royal Society of Medicine, London and a Visiting Professor at St. George’s Hospital, London and an Adjunct Professor at North Eastern University, Boston, Trinity College, Dublin and NUIG Galway. PMR has >370 scientific publications and > 400 talks at international meetings. In 2010 PMR was awarded the James Gregory Medal and an Agilent Thought Leader award, in 2012 she received a Waters Global Innovation Award in NIBRT and in 2017 in BTI AStar Singapore. She received an HD at the Sahlgrenska Institute, Univ. of Gothenburg (2015) and the International Glycoconjugate Organisation Award for contributions to GlycoScience (2017).